ES2527544T1 - Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC - Google Patents

Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC Download PDF

Info

Publication number
ES2527544T1
ES2527544T1 ES12189195.6T ES12189195T ES2527544T1 ES 2527544 T1 ES2527544 T1 ES 2527544T1 ES 12189195 T ES12189195 T ES 12189195T ES 2527544 T1 ES2527544 T1 ES 2527544T1
Authority
ES
Spain
Prior art keywords
treatment
combination
psi
infected
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES12189195.6T
Other languages
English (en)
Spanish (es)
Inventor
Barry M. Bernstein
Rajeev M. Menon
Amit Khatri
Sven MENSING
Sandeep Dutta
Daniel E. Cohen
Thomas Podsadecki
Scott C. Brun
Walid M. Awni
Emily O. Dumas
Cheri E. Klein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47143548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2527544(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of ES2527544T1 publication Critical patent/ES2527544T1/es
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Prostheses (AREA)
ES12189195.6T 2011-10-21 2012-10-19 Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC Pending ES2527544T1 (es)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US201161550360P 2011-10-21 2011-10-21
US201161550360P 2011-10-21
US201161562176P 2011-11-21 2011-11-21
US201161562176P 2011-11-21
US201261587197P 2012-01-17 2012-01-17
US201261587197P 2012-01-17
US201261600468P 2012-02-17 2012-02-17
US201261600468P 2012-02-17
US201261619883P 2012-04-03 2012-04-03
US201261619883P 2012-04-03
US201261656253P 2012-06-06 2012-06-06
US201261656253P 2012-06-06
US201261711793P 2012-10-10 2012-10-10
US201261711793P 2012-10-10

Publications (1)

Publication Number Publication Date
ES2527544T1 true ES2527544T1 (es) 2015-01-26

Family

ID=47143548

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12189195.6T Pending ES2527544T1 (es) 2011-10-21 2012-10-19 Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC

Country Status (28)

Country Link
US (2) US8809265B2 (cg-RX-API-DMAC7.html)
EP (1) EP2583680A3 (cg-RX-API-DMAC7.html)
JP (2) JP5677646B2 (cg-RX-API-DMAC7.html)
CN (2) CN104023726A (cg-RX-API-DMAC7.html)
AR (1) AR088408A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013201532B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014005617A2 (cg-RX-API-DMAC7.html)
CA (1) CA2811250C (cg-RX-API-DMAC7.html)
CH (1) CH707030B1 (cg-RX-API-DMAC7.html)
CL (2) CL2014000778A1 (cg-RX-API-DMAC7.html)
CY (1) CY20152200002T2 (cg-RX-API-DMAC7.html)
DE (6) DE202012012954U1 (cg-RX-API-DMAC7.html)
DK (1) DK2583680T1 (cg-RX-API-DMAC7.html)
DO (1) DOP2014000067A (cg-RX-API-DMAC7.html)
EA (1) EA201490836A1 (cg-RX-API-DMAC7.html)
ES (1) ES2527544T1 (cg-RX-API-DMAC7.html)
GB (4) GB2515942A (cg-RX-API-DMAC7.html)
HK (2) HK1199817A1 (cg-RX-API-DMAC7.html)
IL (1) IL230862A0 (cg-RX-API-DMAC7.html)
MX (1) MX2014004729A (cg-RX-API-DMAC7.html)
PH (2) PH12014500833A1 (cg-RX-API-DMAC7.html)
PT (2) PT107925A (cg-RX-API-DMAC7.html)
SE (2) SE1450020A1 (cg-RX-API-DMAC7.html)
SG (1) SG2014011670A (cg-RX-API-DMAC7.html)
TW (2) TWI532485B (cg-RX-API-DMAC7.html)
UY (1) UY34401A (cg-RX-API-DMAC7.html)
WO (1) WO2013059638A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201406352B (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CA2840242C (en) 2011-09-16 2019-03-26 Gilead Sciences, Inc. Methods for treating hcv
AU2013201406B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
US8492386B2 (en) * 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) * 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AR088408A1 (es) * 2011-10-21 2014-05-28 Abbvie Inc Metodos para el tratamiento de hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2885024A1 (en) * 2012-09-18 2014-03-27 Abbvie Inc. Methods for treating hepatitis c
SG10201702248UA (en) * 2012-09-18 2017-04-27 Abbvie Inc Methods for treating hepatitis c
JP6266635B2 (ja) * 2012-10-18 2018-01-24 アッヴィ・インコーポレイテッド ピリミジンジオン誘導体化合物の製剤
EP3650013A1 (en) 2013-01-31 2020-05-13 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
WO2017007934A1 (en) 2015-07-08 2017-01-12 Abbvie Inc. Methods for treating hcv
PL2968302T3 (pl) 2013-03-14 2018-04-30 Abbvie Inc. Kombinacja bezpośrednio działających środków przeciwwirusowych i rybawiryny do leczenia pacjentów z HCV
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
PT3213750T (pt) 2013-03-14 2020-10-19 Abbvie Inc Combinação de dois antivirais para o tratamento da hepatite c
MX2015017953A (es) * 2013-07-02 2016-10-28 Abbvie Inc Metodos para tratar el virus de hepatitis c.
CN105451736A (zh) * 2013-07-02 2016-03-30 艾伯维公司 用于治疗hcv的方法
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
CN105530933B (zh) 2013-07-17 2018-12-11 百时美施贵宝公司 用于治疗hcv的包含联苯衍生物的组合产品
SI3038601T1 (sl) 2013-08-27 2020-07-31 Gilead Pharmasset Llc Formulacija kombinacije dveh protivirusnih spojin
US20150141351A1 (en) * 2013-11-18 2015-05-21 AbbVie Deutschland GmbH & Co. KG Solid Pharmaceutical Compositions
US20150174194A1 (en) * 2013-12-19 2015-06-25 Abbvie Inc. Methods for treating liver transplant recipients
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
BR112016022976A8 (pt) 2014-04-02 2021-07-20 Abbvie Inc métodos para o tratamento de hcv
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016089814A1 (en) 2014-12-02 2016-06-09 Concert Pharmaceuticals, Inc. Deuterated analogues of daclatasvir
US10654909B2 (en) 2014-12-04 2020-05-19 Novartis Ag Soluble alpha klotho and serum albumin fusion protein
WO2016090107A2 (en) * 2014-12-04 2016-06-09 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
CN104546780A (zh) * 2014-12-12 2015-04-29 安徽一灵药业有限公司 一种达卡他韦薄膜包衣片制剂及其制备方法
ES2844848T3 (es) 2015-04-21 2021-07-22 Eiger Biopharmaceuticals Inc Composiciones farmacéuticas que comprenden Lonafarnib y Ritonavir
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
US20180177778A1 (en) * 2015-06-29 2018-06-28 Abbvie Inc. Methods for Treating HCV
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
JP2018131439A (ja) 2017-02-14 2018-08-23 アッヴィ・インコーポレイテッド Ｈｃｖを処置する方法
CA2981993A1 (en) 2017-08-02 2019-02-02 Abbvie Inc. Methods for treating hcv
WO2019074507A1 (en) 2017-10-12 2019-04-18 Abbvie Inc. METHODS FOR THE TREATMENT OF HCV

Family Cites Families (403)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026687A (en) 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
WO1994001125A1 (en) 1992-07-13 1994-01-20 Sherman Kenneth E Composition and method of treating hepatitis b
US6107027A (en) 1994-12-14 2000-08-22 University Of Washington Ribozymes for treating hepatitis C
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
US6387365B1 (en) 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5980884A (en) 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
GB9605293D0 (en) 1996-03-13 1996-05-15 Glaxo Group Ltd Medicaments
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
AU5157998A (en) 1996-11-01 1998-05-29 Thomas Najarian Methods and compositions for treatment of hepatitis c infection
IL119833A (en) 1996-12-15 2001-01-11 Lavie David Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
US6010890A (en) 1997-04-29 2000-01-04 New York Blood Center, Inc. Method for viral inactivation and compositions for use in same
US6103706A (en) 1997-04-29 2000-08-15 New York Blood Center, Inc. Methods for treating viral infections
US6143752A (en) 1997-08-01 2000-11-07 Oren; Ran Method for preventing or arresting liver damage in humans
DK1136075T3 (da) 1997-09-21 2003-04-28 Schering Corp Kombinationsterapi til udryddelse aff detekterbart HCV-RNA i patienter med kronisk hepatitis C infektion
JP3838034B2 (ja) 1997-10-13 2006-10-25 大塚製薬株式会社 Ｃ型肝炎治療効果の改善剤及びその応用
FR2771637B1 (fr) 1997-12-01 2003-10-24 Hutchinson Utilisation d'un halogenure de dialkyldialkylammonium par voie parenterale dans les infections bacteriennes et virales
KR20010033028A (ko) 1997-12-11 2001-04-25 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 막-관련 바이러스 복제의 억제
AU1703799A (en) 1997-12-17 1999-07-05 Cornell Research Foundation Inc. Cyclooxygenase-2 inhibition
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
CA2326535A1 (en) 1998-03-27 1999-10-07 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
JP2000007578A (ja) 1998-06-24 2000-01-11 Hiroaki Okushin Ｃ型肝炎ウイルスの陰性化のための投薬システム
EP1091975B1 (fr) 1998-07-01 2005-12-14 Debiopharm S.A. Nouvelle cyclosporine ayant un profil d'activite ameliore
RU2158604C2 (ru) 1998-07-03 2000-11-10 Толоконская Наталья Петровна Способ лечения вирусного гепатита c
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
ID29187A (id) 1998-10-16 2001-08-09 Schering Corp Terapi kombinasi alfa internferon-ribavirin untuk memusnahkan hcv-rna yang dapat ditemukan pada pasien-pasien yang mengalami infeksi hepatitis c kronis
US20080275005A1 (en) 1998-11-25 2008-11-06 Murphy Michael P Mitochondrially targeted antioxidants
AU2157000A (en) 1998-12-18 2000-07-12 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
US6824768B2 (en) 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
AR022116A1 (es) 1998-12-18 2002-09-04 Schering Corp Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
JP2000212099A (ja) 1999-01-19 2000-08-02 Mochida Pharmaceut Co Ltd ウイルス性肝炎治療剤
RU2001125094A (ru) 1999-02-13 2003-09-27 Пьюрпалс Текнолоджиз, Инк. (Us) Способы инактивации патогенов с использованием импульсного света широкого спектра
US6589570B1 (en) 1999-04-12 2003-07-08 University Of Madras Pharmaceutical formulation useful for the treatment of hepatitis B, hepatitis C and other viral infections of the liver and a process for its preparation
US6849254B1 (en) 1999-04-19 2005-02-01 Schering Corporation HCV combination therapy
US7312244B2 (en) 1999-04-30 2007-12-25 Cellgate, Inc. Polyamine analog-amino acid conjugates useful as anticancer agents
CN1390227A (zh) 1999-07-22 2003-01-08 新生物生物公司 酶催化的治疗活化
RU2002105485A (ru) 1999-08-13 2004-01-27 Ф.Хоффманн-Ля Рош Аг (Ch) Применение микофенолята мофетила в сочетании с ПЭГ-интерфероном-α (ПЭГ-IFN-α)
US20050245502A1 (en) 1999-08-23 2005-11-03 Phoenix Biosciences Treatments for viral infections
KR100392292B1 (ko) 2000-01-07 2003-07-22 주식회사 펩트론 5원환 융합 방향족 헤테로사이클릭 화합물을 유효성분으로 하는 hcv 치료제 조성물
AU2001253206A1 (en) 2000-04-05 2001-10-23 Tularik, Inc. Ns5b hcv polymerase inhibitors
AU764095B2 (en) 2000-04-07 2003-08-07 Shionogi & Co., Ltd. Preincubation assay method
WO2001079540A2 (en) 2000-04-18 2001-10-25 Virco Bvba Methods for measuring drug resistance
US6415797B1 (en) 2000-07-07 2002-07-09 First Circle Medical, Inc. Treatment of human herpesviruses using hyperthermia
US7012066B2 (en) 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
CA2417550A1 (en) 2000-08-02 2002-02-07 Ortho-Mcneil Pharmaceutical, Inc. Improved anti-viral and anti-tumor chemotherapy by administration of erythropoeitin
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
ATE338564T1 (de) 2000-10-12 2006-09-15 Viromics Gmbh Proteasome inhibitoren zur behandlung von hepatitis-virus infektionen
AP2003002796A0 (en) 2000-10-13 2003-06-30 Richard Boyd Disease prevention by reactivation of the thymus
CA2425522A1 (en) 2000-10-18 2002-04-25 Schering Corporation Ribavirin-pegylated interferon alfa hcv combination therapy
FR2815543B1 (fr) 2000-10-19 2003-10-24 Sedat Seringue d'auto-injection d'un melange extemporane
ES2311558T3 (es) 2000-10-20 2009-02-16 Genetics Institute, Inc. Uso de inhibidores de la il-13 para el tratamiento de tumores.
WO2002053096A2 (en) 2000-12-06 2002-07-11 The Trustees Of The University Of Pennsylvania Single therapy and combination therapy involving drugs with target cellular proteins and drugs which target pathogen-encoded proteins
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
BR0206614A (pt) 2001-01-22 2004-02-17 Merck & Co Inc Composto, composição farmacêutica, método para inibir a polimerase viral de rna dependente de rna e/ou inibir a replicação viral de rna dependente de rna, método para tratar uma infecção viral de rna dependente de rna, e, uso de um composto
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
GB0107924D0 (en) 2001-03-29 2001-05-23 Angeletti P Ist Richerche Bio Inhibitor of hepatitis C virus NS3 protease
US6673775B2 (en) 2001-04-18 2004-01-06 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US7326536B2 (en) 2001-05-03 2008-02-05 Eli Lilly And Company Agents for treatment of HCV and methods of use
US6833351B2 (en) 2001-05-21 2004-12-21 Douglas T. Dieterich Method of treating anemia caused by ribavirin treatment of hepatitis C using erythropoietin alpha
US20030138403A1 (en) 2001-06-29 2003-07-24 Maxygen Aps Interferon formulations
EP1414498A2 (en) 2001-06-29 2004-05-06 Maxygen Aps Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins
HUP0401156A2 (hu) 2001-07-20 2004-12-28 Intermune, Inc. Májfibrózis kezelésére szolgáló módszerek
WO2003024461A1 (en) 2001-09-20 2003-03-27 Schering Corporation Hcv combination therapy
WO2003028754A1 (en) 2001-09-28 2003-04-10 Intermune, Inc. Method for treating hepatitis c virus infection in treatment failure patients
PL369129A1 (en) 2001-09-28 2005-04-18 Intermune, Inc. Method for treating hepatitis c virus infection in treatment failure patients
MXPA04003238A (es) 2001-10-05 2004-07-08 Intermune Inc Metodo para tratar la infeccion de virus de hepatitis con una configuracion de suministro de interferon multifasica.
WO2003037908A1 (en) 2001-10-31 2003-05-08 Ribapharm Inc. Antiviral combination therapy and compositions
AR037131A1 (es) 2001-10-31 2004-10-20 Schering Corp Formulaciones de jarabe de ribavirina
EP1444330A1 (en) 2001-11-07 2004-08-11 Kirin Beer Kabushiki Kaisha Expansion of t cells in vitro and expanded t cell populations
AUPR879601A0 (en) 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
JP2005517648A (ja) 2001-12-07 2005-06-16 インターミューン インコーポレイテッド 肝炎ウイルス感染症を治療するための組成物および方法
US6936629B2 (en) 2001-12-21 2005-08-30 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
US6906190B2 (en) 2002-01-04 2005-06-14 Ribapharm Inc. Inhibitors for de novo-RNA polymerases and methods of identifying targets for same
RU2212248C1 (ru) 2002-01-21 2003-09-20 Государственное образовательное учреждение высшего профессионального образования Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Способ лечения больных хроническим вирусным гепатитом c
US20040048795A1 (en) 2002-02-26 2004-03-11 North Shore-Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
US6649615B2 (en) 2002-04-23 2003-11-18 Institute National De La Sante Et De La Recherche Medicale (Inserm) Method for inhibiting fibrogenesis
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20040034206A1 (en) 2002-05-31 2004-02-19 Schering Corporation Combination therapy for RNA virus infections involving ribavirin and IMPDH inhibitors
TWI334785B (en) 2002-06-03 2010-12-21 Serono Lab Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
ITMI20021860A1 (it) 2002-08-28 2004-02-29 Scalia Antonio Cassar Impiego dei triptani come agenti antivirali.
US20060223145A1 (en) 2002-11-01 2006-10-05 Lohray Braj B Method for producing recombinant human interferon alpha 2b polypeptide in pichia pastoris
WO2004043435A2 (en) 2002-11-13 2004-05-27 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
WO2004047673A2 (en) 2002-11-21 2004-06-10 Novacea, Inc. Treatment of liver disease with active vitamin d compounds
MXPA05008106A (es) 2003-02-18 2005-09-21 Pfizer Inhibidores del virus de la hepatitis c, composiciones y tratamientos que los emplean.
EP1601368A2 (en) 2003-02-28 2005-12-07 Intermune, Inc. Methods and compositions for treatment of viral diseases
US20070077225A1 (en) 2003-02-28 2007-04-05 Blatt Lawrence M Continuous delivery methods for treating hepatitis virus infection
WO2004078194A1 (en) 2003-02-28 2004-09-16 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
TWI269656B (en) 2003-03-05 2007-01-01 Original Image Co Ltd Therapeutical composition for hepatitis C
UA64191A (en) 2003-03-14 2004-02-16 Yevhenii Mykhailovych Neiko Method for treating chronic hepatitises of various etiology
US20040198840A1 (en) 2003-04-02 2004-10-07 Deloach Reuben Edwin Hydrazide substrate safely shuts down disease activated protease to halt viral replication, cancerous cell division, and toxic protein generation
DE602004019518D1 (de) 2003-04-16 2009-04-02 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
US20040258663A1 (en) 2003-05-08 2004-12-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon alpha
US20050009877A1 (en) 2003-05-15 2005-01-13 Henry Lu Methods of identifying HCV NS5B polymerase inhibitors and their uses
EP1654261B1 (en) 2003-05-21 2007-11-14 Boehringer Ingelheim International GmbH Hepatitis c inhibitor compounds
ES2586668T5 (es) 2003-05-30 2024-11-12 Gilead Pharmasset Llc Análogos de nucleósidos fluorados modificados
US20050187170A1 (en) 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
WO2004112720A2 (en) 2003-06-20 2004-12-29 Viral Genomix, Inc. Antiviral compositions and methods of using the same
WO2005010143A2 (en) 2003-07-11 2005-02-03 Oregon Health And Science University Methods of treatment and disgnosis using modulators of virus-induced cellular gene sequences
MD2549G2 (ro) 2003-07-18 2005-08-31 Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова Metodă de tratament a hepatitei virale cronice C.
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2005018330A1 (en) 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
OA13310A (en) 2003-09-05 2007-04-13 Anadys Pharmaceuticals Inc TLR7 ligands for the treatment of hepatitis C.
US20070110714A1 (en) 2003-09-08 2007-05-17 Norio Hayashi Medicinal composition for treatment of chronic hepatitis c
AR045870A1 (es) 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
WO2005038056A1 (en) 2003-10-14 2005-04-28 Intermune, Inc. Combination therapy for the treatment of viral diseases
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
RS20060259A (sr) 2003-10-14 2008-08-07 Intermune Inc., Makrociklične karboksilne kiseline i acilsulfonamidi kao inhibitori replikacije hcv
US20050085528A1 (en) 2003-10-17 2005-04-21 Pfizer Inc. Parmaceutical
DK1692516T3 (da) 2003-10-24 2011-02-28 Immunaid Pty Ltd Terapifremgangsmåde
KR20060120162A (ko) 2003-10-27 2006-11-24 버텍스 파마슈티칼스 인코포레이티드 Ｈｃｖ 치료용 배합물
WO2005043118A2 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Drug discovery method
UA68233A (en) 2003-11-25 2004-07-15 Univ Zaporizhia State Medical Method for treating chronic hepatitis c
US7078064B2 (en) 2003-12-03 2006-07-18 George Zabrecky Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis
EP2546254A1 (en) 2003-12-22 2013-01-16 K.U.Leuven Research & Development Imidazo[4,5-C]pyridine compounds and methods of antiviral treatment
WO2005062949A2 (en) 2003-12-23 2005-07-14 Intermune, Inc. Method for treating hepatitis virus infection
WO2005067963A1 (en) 2003-12-23 2005-07-28 Intermune, Inc. Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
WO2005067454A2 (en) 2003-12-23 2005-07-28 Valeant Pharmaceuticals North America Combination therapy for treating hepatitis c virus infection
DE10361944A1 (de) 2003-12-31 2005-07-28 Viromics Gmbh Mittel zur Hemmung der Virusreplikation durch Regulation der Proteinfaltung
US20080234182A1 (en) 2007-03-22 2008-09-25 Innovative Biologics, Inc. Blockers of pore-forming virulence factors and their use as anti-infectives
US20080004236A1 (en) 2004-02-06 2008-01-03 Comper Wayne D High Dose, Short Interval Use of Sulfated Polysaccharides for Treatment of Infections
KR20060124725A (ko) 2004-02-27 2006-12-05 쉐링 코포레이션 Ｃ형 간염 바이러스 ｎｓ3 프로테아제의 억제제
CA2563058C (en) 2004-04-22 2012-10-16 Howard J. Smith & Associates Pty Ltd Supportive treatment of liver disease
EP2500431A3 (en) 2004-05-04 2013-12-18 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for reducing viral genome amounts in a target cell
US20050249702A1 (en) 2004-05-06 2005-11-10 Schering Corporation (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease
AU2005240680A1 (en) 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target
WO2006016930A2 (en) 2004-05-14 2006-02-16 Intermune, Inc. Methods for treating hcv infection
EP1753775B1 (en) 2004-05-25 2012-12-26 Boehringer Ingelheim International GmbH Process for preparing acyclic hcv protease inhibitors
AR049297A1 (es) 2004-06-08 2006-07-12 Vertex Pharma Una composicion farmaceutica y dispersiones solidas de vx-950 (inhibidor de la proteasa de hcv ns3/4a) y proceso de obtencion
RU2394589C2 (ru) 2004-07-14 2010-07-20 Новартис Аг Применение комбинации циклоспорина и пэгилированного интерферона для лечения гепатита с (hcv)
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
EP1627641A1 (en) 2004-08-04 2006-02-22 Victor Eluwa Pharmaceutical compositions comprising metal oxides and uses thereof
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
WO2006037052A2 (en) 2004-09-27 2006-04-06 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Modulating mxa expression
AU2005291918A1 (en) 2004-10-01 2006-04-13 Vertex Pharmaceuticals Incorporated HCV NS3-NS4A protease inhibition
CN101056648B (zh) 2004-10-01 2012-08-15 德比奥法姆股份有限公司 [d-meala]3-[etval]4环孢菌素用于丙型肝炎感染治疗的应用以及包含所述[d-meala]3-[etval]4-环孢菌素的药物组合物
US7723310B2 (en) 2004-10-18 2010-05-25 Three Rivers Pharmaceuticals, Llc Large dose ribavirin formulations
WO2006043153A2 (en) 2004-10-20 2006-04-27 Michel Xilinas Use of zinc and copper chelators for the treatment of viral diseases
US20060228333A1 (en) 2004-10-20 2006-10-12 Kye-Hyung Paik Methods for control of tumors and chronic infections by modulating immunologically informed carriers homing to tolerogenic organs or tissues
CA2585113A1 (en) 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
TW201424733A (zh) 2004-10-29 2014-07-01 Vertex Pharma 劑量型式
US7592315B2 (en) 2004-11-02 2009-09-22 Schering Corporation Peptide viral entry inhibitors
WO2006055711A1 (en) 2004-11-18 2006-05-26 Kent Hann Compositions containing aloe vera isolate and a prebiotic and their therapeutic application
US8399428B2 (en) 2004-12-09 2013-03-19 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
TW200633718A (en) 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
DE102004061746A1 (de) 2004-12-22 2006-07-06 Bayer Healthcare Ag Alkinyl-substituierte Thiophene
EP1674104A1 (en) 2004-12-24 2006-06-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
WO2006074964A1 (en) 2005-01-17 2006-07-20 Jerini Ag C5a receptor antagonists
WO2006084139A2 (en) 2005-02-03 2006-08-10 Intarcia Therapeutics, Inc. An implantable interferon-containing device
MX2007009561A (es) 2005-02-09 2008-01-14 Migenix Inc Composiciones y metodos para tratar o evitar infecciones de flaviviridae.
US20060198787A1 (en) 2005-02-18 2006-09-07 Larry Blatt Biomarkers for predicting liver fibrosis treatment efficacy
WO2006091610A2 (en) 2005-02-23 2006-08-31 The Brigham And Women's Hospital, Inc. Inhibitors of enveloped virus infectivity
US20090156545A1 (en) 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
US20060229293A1 (en) 2005-04-06 2006-10-12 Addiction Research Institute, Inc. Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C
WO2006110656A2 (en) 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of viral infections and other medical disorders
WO2006113431A2 (en) 2005-04-13 2006-10-26 University Of Massachusetts Dual functional oligonucleotides for use as anti-viral agents
US20060241144A1 (en) 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
JP5030947B2 (ja) 2005-05-13 2012-09-19 ヴァイロケム・ファーマ・インコーポレーテッド フラビウイルス感染の治療及び予防のための化合物及び方法
WO2006127289A1 (en) 2005-05-20 2006-11-30 Valeant Research & Development Treatment of hcv with subtherapeutic doses of ribavirin
WO2006127482A1 (en) 2005-05-20 2006-11-30 Bioenvision, Inc. Methylene blue therapy of viral disease
EP1899368A2 (en) 2005-05-26 2008-03-19 Schering Corporation Interferon-igg fusion
BRPI0610873A2 (pt) 2005-05-31 2010-08-03 Novartis Ag tratamento de doenças hepáticas em que o ferro desempenhe um papel na patogênese
US7793040B2 (en) 2005-06-01 2010-09-07 Microsoft Corporation Content addressable memory architecture
WO2006130552A2 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
US20060275366A1 (en) 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
US20070237818A1 (en) 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
WO2006130554A2 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
AU2006252519B2 (en) 2005-06-02 2012-08-30 Merck Sharp & Dohme Corp. HCV protease inhibitors in combination with food
US20060287248A1 (en) 2005-06-02 2006-12-21 Schering Corporation Asymmetric dosing methods
US20070207949A1 (en) 2005-06-02 2007-09-06 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
US20060281689A1 (en) 2005-06-02 2006-12-14 Schering Corporation Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
WO2006130666A2 (en) 2005-06-02 2006-12-07 Schering Corporation Medicaments and methods combining a hcv protease inhibitor and an akr competitor
PE20070011A1 (es) 2005-06-02 2007-03-08 Schering Corp Formulaciones farmaceuticas de compuestos inhibidores de proteasa del vhc o catepsina
WO2006130687A2 (en) 2005-06-02 2006-12-07 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor
US20070004635A1 (en) 2005-06-02 2007-01-04 Schering Corporation Method of treating interferon non-responders using HCV protease inhibitor
US20070232527A1 (en) 2005-06-02 2007-10-04 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
NZ563686A (en) 2005-06-07 2011-07-29 Univ Yale Methods of treating cancer and other conditions or disease states using LFMAU and LDT
RU2293572C1 (ru) 2005-07-18 2007-02-20 Гюнтер Хаазе Способ лечения хронического вирусного гепатита с генотип-2 с умеренной активностью
US7470664B2 (en) 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
CN101277950B (zh) 2005-08-02 2013-03-27 弗特克斯药品有限公司 丝氨酸蛋白酶抑制剂
BRPI0614761A2 (pt) 2005-08-12 2009-05-19 Human Genome Sciences Inc proteìnas de fusão de albumina
DE102005038768A1 (de) 2005-08-16 2007-02-22 Toximed Gmbh Pharmazeutischer Wirkstoff gegen Borreliose
CA2619659A1 (en) 2005-08-19 2007-02-22 Vertex Pharmaceuticals Incorporated Processes and intermediates
US8193328B2 (en) 2005-09-08 2012-06-05 Philadelphia Health & Education Corporation Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents
US7531164B2 (en) 2005-10-21 2009-05-12 Duke University Preventing bacterial or viral infectivity and composition containing infection preventing additive
IE20050723A1 (en) 2005-10-28 2007-05-30 Patrick T Prendergast Anti-mineralocorticoid therapy of infection
WO2007056016A2 (en) 2005-11-02 2007-05-18 Kemia, Inc. Bisamide cytokine inhibitors
RU2306134C2 (ru) 2005-11-07 2007-09-20 Государственное образовательное учреждение высшего профессионального образования "Самарский Государственный медицинский университет" Способ базисного лечения хронического вирусного гепатита c
EP2392588A3 (en) 2005-11-11 2012-03-07 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
WO2007058384A1 (en) 2005-11-17 2007-05-24 Osaka University Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same
RU2326115C2 (ru) 2005-11-21 2008-06-10 Ефаг АО Соли 1-алкиламино-1-дезоксиполиолов с 9-оксоакридин-10-уксусной кислотой, лекарственные препараты на их основе, применение, способы профилактики и лечения
AR057623A1 (es) 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
US8293726B2 (en) 2005-12-02 2012-10-23 Vianova Labs, Inc. Treatment of cancer and other diseases
EP1957510A1 (en) 2005-12-09 2008-08-20 F.Hoffmann-La Roche Ag Antiviral nucleosides
WO2007075896A2 (en) 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
RU2306934C1 (ru) 2005-12-28 2007-09-27 ГОУ ВПО Омская Государственная Медицинская Академия Способ лечения больных хроническим вирусным гепатитом c
EA015560B1 (ru) 2006-01-09 2011-08-30 Ромарк Лэборетериз, Эл.Си. Способ лечения вирусного гепатита
MD20060037A (ro) 2006-01-24 2007-07-31 Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова Metodă de tratament al hepatitei virale acute C
TW200808308A (en) 2006-02-09 2008-02-16 Schering Corp Novel HCV inhibitor combinations and methods
US20070274951A1 (en) 2006-02-09 2007-11-29 Xiao Tong Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto
US8039475B2 (en) 2006-02-27 2011-10-18 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
KR20080112303A (ko) 2006-03-16 2008-12-24 버텍스 파마슈티칼스 인코포레이티드 중수소화 ｃ형 간염 프로테아제 억제제
US20070218012A1 (en) 2006-03-20 2007-09-20 Bittorf Kevin J Pharmaceutical Compositions
AU2007226983A1 (en) 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US20070287664A1 (en) 2006-03-23 2007-12-13 Schering Corporation Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto
US8895531B2 (en) 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
WO2007130646A2 (en) 2006-05-04 2007-11-15 The Rockefeller University Hcv coreceptor and methods of use thereof
WO2008060695A2 (en) 2006-05-22 2008-05-22 The Trustees Of The University Of Pennsylvania Antiviral inhibition of casein kinase ii
DE102006026464A1 (de) 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
AU2007254827A1 (en) 2006-06-02 2007-12-13 San Diego State University Research Foundation Compositions and methods for ameliorating hyperlipidemia
WO2007140968A1 (en) 2006-06-04 2007-12-13 Cellartis Ab Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells
AU2007257959A1 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
WO2007149382A2 (en) 2006-06-19 2007-12-27 The Cleveland Clinic Foundation Therapeutic compositions and methods useful in treating hepatitis
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
US20080081791A1 (en) 2006-07-06 2008-04-03 Weida Huang Methods of using combinations of siRNAs for treating a disease or a disorder, and for enhancing siRNA efficacy in RNAi
MX2009000236A (es) 2006-07-07 2009-01-23 Gilead Sciences Inc Compuestos de fosfinato antivirales.
DK2041156T3 (en) 2006-07-13 2014-02-24 Achillion Pharmaceuticals Inc 4-AMINO-4-OXOBUTANOYL Peptides AS INHIBITORS OF VIRUS REPLICATION
WO2008022006A2 (en) 2006-08-11 2008-02-21 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis c virus protease inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100158862A1 (en) 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
KR20090057035A (ko) 2006-08-21 2009-06-03 유나이티드 세러퓨틱스 코오포레이션 바이러스 감염의 치료를 위한 병용 요법
WO2008073165A2 (en) 2006-08-25 2008-06-19 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for identifying anti-hcv agents
US20080182895A1 (en) 2006-08-25 2008-07-31 Howe Anita Y M Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto
TW200815384A (en) 2006-08-25 2008-04-01 Viropharma Inc Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein
US9216197B2 (en) 2006-09-11 2015-12-22 Biomas Ltd. Topical formulations of tellurium-containing compounds
US20080161324A1 (en) 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
BRPI0716744A2 (pt) 2006-09-14 2016-10-04 Human Genome Sciences Inc proteínas de fusão de albumina
WO2008039179A1 (en) 2006-09-26 2008-04-03 Addiction Research Institute, Inc. Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c
ES2429290T3 (es) 2006-10-10 2013-11-14 Gilead Pharmasset Llc Preparación de nucleósidos de ribofuranosilpirimidinas
US7777395B2 (en) 2006-10-12 2010-08-17 Eastman Kodak Company Continuous drop emitter with reduced stimulation crosstalk
BRPI0718161A2 (pt) 2006-10-27 2013-11-26 Merck & Co Inc Composto, composição farmacêutica, e, uso do composto.
CN101568538B (zh) 2006-11-15 2012-09-05 Viro化学制药公司 用于治疗或预防黄病毒属感染的噻吩类似物
WO2008143647A2 (en) 2006-11-29 2008-11-27 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating viral infection
EP2428204A3 (en) 2006-12-07 2012-07-04 Schering Corporation pH sensitive matrix formulation
RU2336096C1 (ru) 2006-12-14 2008-10-20 ООО Медицинский центр "Столица" Способ лечения гепатита с
RU2345787C2 (ru) 2006-12-25 2009-02-10 Государственное образовательное учреждение высшего профессионального образования "Самарский Государственный медицинский университет" Способ лечения хронического вирусного гепатита с
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
KR20090101372A (ko) 2007-01-08 2009-09-25 페노믹스 코포레이션 매크로시클릭 ｃ형 간염 프로테아제 억제제
WO2008089034A2 (en) 2007-01-11 2008-07-24 Kemia, Inc. Cytokine inhibitors
US7645732B2 (en) 2007-01-24 2010-01-12 Board Of Regents, The University Of Texas System Treating hepatitis C virus infection
AR065136A1 (es) 2007-02-01 2009-05-20 Tibotec Pharm Ltd Formas polimorficas de un inhibidor macrociclico de vhc. procesos de obtencion y composiciones farmaceuticas.
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
CA2683383C (en) 2007-02-21 2016-01-05 Allaccem, Incorporated Bridged polycyclic compound based compositions for the inhibition and amelioration of disease
EA200970806A1 (ru) 2007-02-27 2010-08-30 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы и содержащие их фармацевтические композиции
WO2008106167A1 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
MD3477G2 (ro) 2007-03-21 2008-08-31 Николае БОДРУГ Metodă de tratament al hepatitei virale cronice C
PL2308514T3 (pl) 2007-03-23 2013-11-29 To Bbb Holding B V Koniugaty do ukierunkowanego dostarczania leku poprzez barierę krew-mózg
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2008124384A2 (en) 2007-04-03 2008-10-16 Aegerion Pharmaceuticals, Inc. Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c
US20080269205A1 (en) 2007-04-27 2008-10-30 Ondine International, Ltd. Methods to prevent vertical transmission of infectious diseases
CN102702260A (zh) 2007-04-27 2012-10-03 奇默里克斯公司 在核苷给药的受体中降低肾中毒性的方法
JP2010528987A (ja) 2007-05-03 2010-08-26 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
EP2494991A1 (en) 2007-05-04 2012-09-05 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
US7932277B2 (en) 2007-05-10 2011-04-26 Intermune, Inc. Peptide inhibitors of hepatitis C virus replication
EP2157974A1 (en) 2007-05-21 2010-03-03 Vertex Pharmceuticals Incorporated Dose forms comprising vx- 950 and their dosage regimen
RU2348412C1 (ru) 2007-06-01 2009-03-10 Лариса Леонидовна Попова Способ профилактики рецидива хронического вирусного гепатита с после достижения вирусологической ремиссии
WO2008154248A1 (en) 2007-06-06 2008-12-18 Inova Health System Prognostic chronic hepatitis c biomarkers
CN101790524B (zh) 2007-06-29 2014-07-16 吉里德科学公司 抗病毒化合物
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
CN101820887A (zh) 2007-07-25 2010-09-01 拜奥雷克斯治疗公司 干扰素控释药品以及使用相同药品治疗hcv感染
EP2178584A2 (en) 2007-07-26 2010-04-28 Entra Pharmaceuticals Inc. Skin-patch pump comprising a changing-volume electrochemical actuator
BRPI0814737B8 (pt) 2007-08-03 2021-05-25 Biotron Ltd composição para o tratamento de hcv, e, uso de uma composição
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
US20110166092A1 (en) 2007-08-20 2011-07-07 Anadys Pharmaceuticals, Inc. Dosing methods for treating disease
WO2009032198A1 (en) 2007-08-30 2009-03-12 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
WO2009033183A2 (en) 2007-09-08 2009-03-12 University Of Florida Research Foundation Compounds and methods for treatment of hcv and conditions associated with cd81 binding
US20090076100A1 (en) 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched gsk625433
NZ583825A (en) 2007-09-14 2012-06-29 Schering Corp Method of treating hepatitis C patients comprising an HCV protease inhibitor, an antiviral compound and an interferon
PT2203431E (pt) * 2007-09-17 2011-10-12 Abbott Lab Pirimidinas anti-infecciosas e seus usos
PE20090705A1 (es) 2007-09-17 2009-07-17 Abbott Lab Derivados de uracilo en el tratamiento de hepatitis c
TW200927102A (en) 2007-09-18 2009-07-01 Univ Stanford Methods of treating a flaviviridae family viral infection, compositions for treating a flaviviridae family viral infection, and screening assays for identifying compositions for treating a flaviviridae family viral infection
US20090082366A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched telaprevir
US20090082414A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched viramidine
CA2701190C (en) 2007-10-03 2017-12-05 Sabell Corporation Herbal compositions and methods for treating hepatic disorders
US20110270212A1 (en) 2007-10-05 2011-11-03 Medtronic, Inc. Pharmacokinetic control for optimized interferon delivery
WO2009061395A2 (en) 2007-11-05 2009-05-14 Vertex Pharmaceuticals Incorporated Hcv combination therapies
JP5349486B2 (ja) 2007-11-15 2013-11-20 マダウス ゲーエムベーハー 肝炎の治療のためのシリビニン成分
TW201546079A (zh) 2007-12-21 2015-12-16 Celgene Avilomics Res Inc Ｈｃｖ蛋白酶抑制劑及其用途（一）
WO2009080542A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Process for the preparation of a macrocycle
US8202996B2 (en) * 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US20100298256A1 (en) 2007-12-27 2010-11-25 Steven Dong Antiviral compounds
US8361980B2 (en) 2008-03-07 2013-01-29 Santaris Pharma A/S Pharmaceutical compositions for treatment of microRNA related diseases
JP5283106B2 (ja) 2008-03-14 2013-09-04 国立大学法人 熊本大学 Ｃ型肝炎ウイルス阻害剤
US20100009970A1 (en) 2008-03-19 2010-01-14 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US20110045001A1 (en) 2008-03-28 2011-02-24 Biontex Laboratories Gmbh Transfection results of non-viral gene delivery systems by influencing of the innate immune system
WO2009134616A2 (en) 2008-04-15 2009-11-05 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
CA2722306A1 (en) 2008-04-23 2009-10-29 Vertex Pharmaceuticals Incorporated Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interferon-alpha-2a/2b and ribavirin
AP3076A (en) * 2008-04-23 2014-12-31 Gilead Sciences Inc Carba-nucleoside analogs for antiviral treatment
DE102008029669A1 (de) 2008-05-16 2009-11-19 Schlaak, Jörg Friedrich, Prof. Dr. med. Neue Therapeutika für die Hepatitis-Therapie
WO2009149179A2 (en) 2008-06-03 2009-12-10 Aethlon Medical Inc. Enhanced antiviral therapy methods and devices
RU2496514C2 (ru) 2008-06-05 2013-10-27 Займоджинетикс, Инк. Применение пэгилированных интерферонов типа iii для лечения гепатита с
US20110165119A1 (en) 2008-06-10 2011-07-07 Maria Gloria Beumont Telaprevir dosing regimen
CN102123706B (zh) 2008-06-17 2013-08-14 米纳斯吉拉斯联合大学 血小板活化因子受体在治疗黄病毒科病毒引起的感染中的用途
ME02132B (me) 2008-07-22 2014-08-22 Merck Sharp & Dohme Kombinacije makrocikličnog jedinjenja hinoksalina koje je inhibitor hcv ns3 proteaze sa drugim hcv sredstvima
CA2737144A1 (en) 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Methods for treating viral disorders
RU2373952C1 (ru) 2008-07-30 2009-11-27 Юрий Михайлович Амбалов Способ лечебного питания больных хроническим гепатитом с, получающих комплексную противовирусную терапию
JP2011530519A (ja) 2008-08-06 2011-12-22 サイクローン・ファーマシューティカルズ・インコーポレイテッド 免疫調節化合物を用いたｃ型肝炎の治療または予防の方法
AR072991A1 (es) 2008-08-07 2010-10-06 Schering Corp Formulaciones farmaceuticas de un inhibidor de la enzima proteasa de hcv en una dispersion molecular solida
CA2732091A1 (en) 2008-08-07 2010-02-11 F. Hoffmann-La Roche Ag Process for the preparation of a macrocycle
US20100092479A1 (en) 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
WO2010020676A1 (en) 2008-08-20 2010-02-25 Vib Vzw The use of topoisomerase type i inhibitors to treat viral infections
WO2010025380A2 (en) 2008-08-28 2010-03-04 Vertex Pharmaceuticals Incorporated Analysis of hcv genotypes
EP2351585B1 (en) 2008-08-29 2014-03-26 Osaka University Anti-hepatitis c virus composition comprising a nucleic acid that is directed against pa28-gamma
WO2010027921A1 (en) 2008-09-03 2010-03-11 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
SI2331538T1 (sl) 2008-09-16 2014-06-30 Boehringer Ingelheim International Gmbh Kristalinične oblike 2-tiazolil-4-kinolinil-oksi derivata, učinkovitega inhibitorja HCV
AU2009293493B2 (en) 2008-09-17 2014-09-18 Boehringer Ingelheim International Gmbh Combination of HCV NS3 protease inhibitor with interferon and ribavirin
WO2010031832A2 (en) 2008-09-18 2010-03-25 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
AU2009296653A1 (en) 2008-09-24 2010-04-01 Janssen Pharmaceutica Nv Therapeutic regimen comprising peg- interferon, ribavirin and VX-950 for the treatment of Hepatitis "
WO2010034670A2 (en) 2008-09-26 2010-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Host cell kinases as targets for antiviral therapies against hcv infection
CA2738985A1 (en) 2008-09-30 2010-04-08 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for hepatitis c
EP3025727A1 (en) 2008-10-02 2016-06-01 The J. David Gladstone Institutes Methods of treating liver disease
EP2352829A1 (en) 2008-10-08 2011-08-10 Charlotte-Mecklenburg Hospital Authority doing business as Carolinas Medical Center Treating hepatitis c virus infection with over-expression of microrna-196
CA2740728A1 (en) 2008-10-15 2010-04-22 Intermune, Inc. Therapeutic antiviral peptides
WO2010049438A2 (en) 2008-10-30 2010-05-06 Innate Pharma Improved methods of using phosphoantigens for the treatment of diseases
EP2358439A1 (en) 2008-11-05 2011-08-24 Vertex Pharmaceuticals Incorporated Methods for treating hepatitis c virus infection
WO2010059667A1 (en) 2008-11-21 2010-05-27 Boehringer Ingelheim International Gmbh Pharmaceutical composition of a potent hcv inhibitor for oral administration
US8614180B2 (en) 2008-12-10 2013-12-24 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8664188B2 (en) 2008-12-11 2014-03-04 Xiangxue Group (Hong Kong) Company Limited siRNA compositions and methods for potently inhibiting viral infection
JP2012512636A (ja) 2008-12-18 2012-06-07 エフ．ホフマン−ラ ロシュ アーゲー Ｈｃｖ処置応答についてのバイオマーカー
EP2376514A2 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Nucleoside analogs
EP2376653A2 (en) 2008-12-29 2011-10-19 Yissum Research Development Company of The Hebrew University of Jerusalem Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
US8840934B2 (en) 2009-01-02 2014-09-23 Rainbow Pharmaceutical Sa Uses of ammonium chloride
US8759318B2 (en) * 2009-01-09 2014-06-24 Inhibitex, Inc. Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
RU2398582C1 (ru) 2009-01-19 2010-09-10 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.М. Мечникова Федерального агентства по здравоохранению и социальному развитию" Способ лечения хронического вирусного гепатита с 1-генотипа с умеренной активностью и репликативностью
EP2396028A2 (en) 2009-02-12 2011-12-21 Vertex Pharmceuticals Incorporated Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
WO2010101649A2 (en) 2009-03-05 2010-09-10 Pablo Gastaminza Sigma 1 receptor inhibition as a novel therapeutical approach against hepatitis c virus infection
MX2011008963A (es) 2009-03-05 2012-02-01 Ascendis Pharma As Profarmacos portadores de interferon alfa.
ES2599979T3 (es) 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
KR101471238B1 (ko) 2009-04-25 2014-12-12 에프. 호프만-라 로슈 아게 약물동력학을 개선하는 방법
KR20180028070A (ko) * 2009-05-13 2018-03-15 길리애드 파마셋 엘엘씨 항바이러스 화합물
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
AU2010249379B2 (en) 2009-05-21 2013-09-26 Merck Sharp & Dohme Corp. Genetic markers associated with interferon-alpha response
CN103819459B (zh) * 2009-06-11 2017-05-17 艾伯维巴哈马有限公司 抗病毒化合物
US20100324060A1 (en) 2009-06-23 2010-12-23 Gilead Sciences, Inc. Pharmaceutical compositions useful for treating hcv
AR077125A1 (es) 2009-06-23 2011-08-03 Gilead Sciences Inc Combinaciones farmaceuticas utiles para tratar el vhc
UY32721A (es) 2009-06-23 2011-01-31 Gilead Sciences Ltd Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
US9023877B2 (en) 2009-06-26 2015-05-05 Romark Laboratories L.C. Compounds and methods for treating influenza
EA023433B1 (ru) 2009-07-07 2016-06-30 Бёрингер Ингельхайм Интернациональ Гмбх Фармацевтическая композиция ингибитора протеазы вируса гепатита c
RU2400229C1 (ru) 2009-07-13 2010-09-27 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" СПОСОБ ЛЕЧЕНИЯ БОЛЬНЫХ ХРОНИЧЕСКИМ ВИРУСНЫМ ГЕПАТИТОМ С, ГЕНОТИПОМ 3а
WO2011009961A1 (en) 2009-07-24 2011-01-27 Virologik Gmbh Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
WO2011014882A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
CA2768772A1 (en) 2009-07-31 2011-02-03 Centre Hospitalier Universitaire Vaudois Methods for diagnosing or predicting hepatitis c outcome in hcv infected patients
US8637449B2 (en) 2009-08-27 2014-01-28 Merck Sharp & Dohme Corp. Processes for preparing protease inhibitors of hepatitis C virus
WO2011038224A1 (en) 2009-09-24 2011-03-31 Trustees Of Boston University Methods for treating viral disorders
WO2011041551A1 (en) 2009-10-01 2011-04-07 Intermune, Inc. Therapeutic antiviral peptides
US8415374B2 (en) 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
US9174988B2 (en) 2009-10-27 2015-11-03 Trustees Of Boston University Small molecule inhibitors of hepatitis C virus
US8729058B2 (en) 2009-10-27 2014-05-20 Michael Zasloff Methods and compositions for treating and preventing viral infections
CN102596201A (zh) 2009-10-30 2012-07-18 贝林格尔.英格海姆国际有限公司 包含BI201335、干扰素α和利巴韦林的HCV组合治疗的用药方案
US20120282224A1 (en) 2009-11-09 2012-11-08 Albrecht Janice K Markers associated with ribavirin-induced anemia
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
WO2011066260A2 (en) 2009-11-25 2011-06-03 Michael Zasloff Formulations comprising aminosterols
EP2512480A4 (en) * 2009-12-14 2013-05-15 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
NZ599963A (en) 2009-12-18 2014-02-28 Boehringer Ingelheim Int Hcv combination therapy
WO2011079016A1 (en) 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
RU2424794C1 (ru) 2009-12-30 2011-07-27 Государственное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО УГМА Росздрава) Способ лечения врожденного гепатита с у детей первого года жизни
MX2012008658A (es) * 2010-01-25 2012-12-05 Enanta Pharm Inc Inhibidores del virus de la hepatitis c.
EP2528605A1 (en) * 2010-01-29 2012-12-05 Vertex Pharmaceuticals Incorporated Therapies for treating hepatitis c virus infection
BR112012022774A2 (pt) * 2010-03-10 2017-09-12 Abbott Lab Composição sólida compreendendo primeira e segunda dispersões sólidas amorfas
US8530497B2 (en) 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor
LT2609923T (lt) * 2010-03-31 2017-09-11 Gilead Pharmasset Llc (s)-izopropilo 2-(((s)-(perfluorfenoksi)(fenoksi)fosforil)amino)-propanoato kristalinimo būdas
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
TW201211047A (en) 2010-06-10 2012-03-16 Gilead Sciences Inc Methods for treating HCV
CA2745102A1 (en) 2010-06-29 2011-12-29 Medicorp Institute Of Canada Pharmaceutical composition and method of use to improve organ function
RU2429877C1 (ru) 2010-06-30 2011-09-27 Общество с ограниченной ответственностью "ИНГИЛС" Способ лечения хронического вирусного гепатита с
WO2012009503A1 (en) 2010-07-14 2012-01-19 Vertex Pharmaceuticals Incorporated Palatable pharmaceutical composition comprising vx-950
EP2598159A4 (en) 2010-07-30 2014-01-08 Merck Sharp & Dohme INHIBITION OF THE CYP3A DRUG MIXTURE EXCHANGE
US20120196272A1 (en) 2010-08-05 2012-08-02 Roche Molecular Systems, Inc. Prediction of HCV Viral Kinetics in Interferon-Free Treatment
US20120196794A1 (en) 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
CA2810928A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
AU2011314170A1 (en) 2010-09-29 2013-04-04 Merck Sharp & Dohme Corp. Polycyclic Heterocycle Derivatives and methods of use thereof for the treatment of viral diseases
EA201300421A1 (ru) 2010-09-30 2013-08-30 Бёрингер Ингельхайм Интернациональ Гмбх Комбинированная терапия для лечения инфекции hcv
CN103269586B (zh) * 2010-10-26 2015-07-15 普雷西迪奥制药公司 丙型肝炎病毒抑制剂
US20120107278A1 (en) 2010-10-29 2012-05-03 Pharmasset, Inc. Abbreviated hcv therapy for hcv infected patients with il28b c/c genotype
TW201701876A (zh) 2010-12-20 2017-01-16 吉李德科學股份有限公司 治療ｃ型肝炎病毒（ｈｃｖ）之方法
EP2725902A4 (en) 2011-04-06 2015-06-24 Univ Princeton ANTIVIRAL COMBINATION THERAPY
JP2014522814A (ja) 2011-06-23 2014-09-08 ステラ・アンパルトセルスカブ Ｈｃｖ併用療法
US20140213632A1 (en) 2011-06-30 2014-07-31 Stella Aps HCV Combination Therapy
KR20140064765A (ko) 2011-06-30 2014-05-28 스텔라 에이피에스 Hcv 조합 치료
WO2013024155A1 (en) 2011-08-17 2013-02-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013025975A1 (en) 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
WO2013028953A1 (en) 2011-08-24 2013-02-28 Glaxosmithkline Llc Combination treatments for hepatitis c
CA2840242C (en) * 2011-09-16 2019-03-26 Gilead Sciences, Inc. Methods for treating hcv
AR088408A1 (es) 2011-10-21 2014-05-28 Abbvie Inc Metodos para el tratamiento de hcv
US8466159B2 (en) * 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) * 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
AU2013201406B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
IN2014CN03113A (cg-RX-API-DMAC7.html) 2011-10-31 2015-07-03 Merck Sharp & Dohme
US20130137084A1 (en) 2011-11-28 2013-05-30 Roche Molecular Systems, Inc. Single Nucleotide Polymorphism on Chromosome 15 That Predicts HCV Treatment Responses
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs

Also Published As

Publication number Publication date
JP2014530874A (ja) 2014-11-20
BR112014005617A2 (pt) 2017-06-13
ZA201406352B (en) 2015-02-25
CA2811250C (en) 2015-08-11
DE202012012955U1 (de) 2014-07-14
SE1450020A1 (sv) 2014-01-10
IL230862A0 (en) 2014-03-31
TW201600087A (zh) 2016-01-01
GB201408664D0 (en) 2014-07-02
TW201321002A (zh) 2013-06-01
SE1450131A1 (sv) 2014-05-07
CN104436197A (zh) 2015-03-25
GB201418014D0 (en) 2014-11-26
EP2583680A2 (en) 2013-04-24
DE112012002813T5 (de) 2014-06-05
HK1200022A1 (en) 2015-07-31
DE202012012954U1 (de) 2014-08-12
CY20152200002T2 (el) 2015-04-29
US8809265B2 (en) 2014-08-19
CL2015002968A1 (es) 2016-05-20
PH12014500833A1 (en) 2014-05-26
DK2583680T1 (da) 2015-01-19
DE112012006327A5 (de) 2015-06-18
HK1199817A1 (en) 2015-07-24
GB2515942A (en) 2015-01-07
DOP2014000067A (es) 2014-07-15
CL2014000778A1 (es) 2014-09-05
CA2811250A1 (en) 2013-04-21
US20130102526A1 (en) 2013-04-25
TWI532485B (zh) 2016-05-11
US20140323395A1 (en) 2014-10-30
DE112012003457T5 (de) 2015-03-12
GB201400674D0 (en) 2014-03-05
AU2013201532A1 (en) 2013-05-09
NZ625539A (en) 2016-06-24
CH707030B1 (de) 2015-03-13
GB201601076D0 (en) 2016-03-02
JP2015071599A (ja) 2015-04-16
UY34401A (es) 2013-05-31
WO2013059638A1 (en) 2013-04-25
AR088408A1 (es) 2014-05-28
AU2013201532B2 (en) 2014-10-02
GB2506085A (en) 2014-03-19
PT107924A (pt) 2014-12-03
CN104023726A (zh) 2014-09-03
EP2583680A3 (en) 2013-06-12
MX2014004729A (es) 2014-07-28
PH12014502847A1 (en) 2016-01-25
EA201490836A1 (ru) 2014-11-28
DE202012013117U1 (de) 2015-01-16
PT107925A (pt) 2014-12-03
SG2014011670A (en) 2014-10-30
JP5677646B2 (ja) 2015-02-25

Similar Documents

Publication Publication Date Title
ES2527544T1 (es) Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC
ES2527510T1 (es) Métodos para el tratamiento del VHC que comprenden al menos dos agentes antivirales de acción directa, ribavirina pero no interferón
DE12189198T1 (de) Verfahren zur Behandlung von HCV mit wenigstens zwei direkt angreifenden viralen Mitteln, Ribavirin aber nicht Interferon.
MX2020005054A (es) Combinacion de dos agentes antivirales para el tratamiento de hepatitis c.
DE12189195T1 (de) Einzel- (PSI-7977) oder Kombinationsbehandlung in der Verwendung zur Behandlung von HCV
MX2015012536A (es) Combinacion de agentes antivirales de accion directa y ribavirina para el tratamiento de pacientes con vhc.
JP2014530874A5 (cg-RX-API-DMAC7.html)
MX2016012799A (es) Metodos para tratar el virus de la hepatitis c.
MX389088B (es) Métodos para tratar el vhc.
MX376327B (es) Regimen de glicosidasa para el tratamiento de enfermedades infecciosas.
MX2016012722A (es) Metodos para tratar el virus de la hepatitis c.
MX2017011247A (es) Formulacion de fosforamidato de nucleotido.
EA202090412A1 (ru) Способы лечения вгс
MX2018001905A (es) Metodos para el tratamiento del virus de hepatitis c (vhc).